Back
  1. Home
  2. Profile of Roy Heusschen (ULiège)
Profil

Heusschen Roy

See author's contact details
Main Referenced Co-authors
Caers, Jo  (33)
Muller, Joséphine  (29)
Beguin, Yves  (27)
Binsfeld, Marilène  (18)
Thijssen, Victor (16)
Main Referenced Keywords
multiple myeloma (11); bone disease (10); saracatinib (6); SRC kinase (6); Angiogenesis (5);
Main Referenced Disciplines
Biochemistry, biophysics & molecular biology (29)
Hematology (16)

Publications (total 44)

The most downloaded
1998 downloads
CAERS, J., Binsfeld, M., Muller, J., Heusschen, R., & Beguin, Y. (2014). Gammapathie monoclonale de signification indéterminée : information destinée aux médecins référents. Revue Médicale de Liège, 69, 41-46. https://hdl.handle.net/2268/172664

The most cited

238 citations (Scopus®)

Thijssen, V., Heusschen, R., CAERS, J., & Griffioen, A. (2015). Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochimica et Biophysica Acta - Reviews on Cancer, 1855 (2), 235-47. doi:10.1016/j.bbcan.2015.03.003 https://hdl.handle.net/2268/181740

Vande Catsyne, C.-A., Sayyed, S. A., Molina Ortiz, P., Moës, B., Communi, D., Muller, J., Heusschen, R., CAERS, J., Azzi, A., Erneux, C., & Schurmans, S. (2020). Altered chondrocyte differentiation, matrix mineralization and MEK-Erk1/2 signaling in an INPPL1 catalytic knock-out mouse model of opsismodysplasia. Advances in Biological Regulation, 76, 100651. doi:10.1016/j.jbior.2019.100651
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Duray, E., WITHOFS, N., Bolomsky, A., Baron, F., Beguin, Y., Menu, E., Ludwig, H., & Caers, J. (2018). Molecular mechanisms, current management and next generation therapy in myeloma bone disease. Leukemia and Lymphoma, 59, 14-28. doi:10.1080/10428194.2017.1323272
Peer Reviewed verified by ORBi

Bolomsky, A., Heusschen, R., Schlangen, K., Stangelberger, K., Muller, J., Schreiner, W., Zojer, N., Caers, J., & Ludwig, H. (2018). Maternal embryonic leucine zipper kinase is a novel target for proliferation associated high-risk myeloma. Haematologica, 103, 325-335. doi:10.3324/haematol.2017.172973
Peer Reviewed verified by ORBi

Heusschen, R., Bolomsky, A., Schlangen, K., Schonfelder, K., Muller, J., Shreiner, W., Zojer, N., CAERS, J., & Ludwig, H. (February 2017). Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an attractive Novel Drug Target in Multiple Myeloma and its associated Bone Disease [Paper presentation]. 32nd General Annual Meeting of the Belgian Hematological Society.

Heusschen, R., Muller, J., WITHOFS, N., BARON, F., BEGUIN, Y., & CAERS, J. (2017). Multiple myeloma bone disease: from mechanisms to next generation therapy. Belgian Journal of Hematology, 8, 66-74.
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Bolomsky, A., Ludwig, H., & CAERS, J. (2017). Maternal Embryonic Leucine Zipper Kinase (MELK) is a key player and an attractive novel target in proliferation-associated high risk multiple myeloma [Paper presentation]. Meeting of the Austrian Society for Hematology and Oncology 2017.

Heusschen, R., Muller, J., Bolomsky, A., Schonfelder, K., Plougonven, E., Léonard, A., BEGUIN, Y., Cohen-Solal, M., Heinz, L., & CAERS, J. (2017). Maternal Embryonic Leucine Zipper Kinase (MELK) inhibition has direct effects on bone cells and prevents the development of osteolytic bone disease in multiple myeloma [Paper presentation]. 44th Annual European Calcified Tissue Society Congress.

Muller, J., BINSFELD, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (2017). Galectin-1 decreases during osteoclast formation [Poster presentation]. 44th Annual European Calcified Tissue Society Congress, Austria.

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (28 February 2016). Galectin-1 is involved in osteoclast biology [Poster presentation]. 2nd Herbert Fleisch Workshop, Brugge, Belgium.

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). The Src Inhibitor AZD0530 Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma [Poster presentation]. 43rd Annual European Calcified Tissue Society Congress, Rome, Italy.

Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma. Belgian Journal of Hematology.
Peer Reviewed verified by ORBi

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (2016). Galectin-1 is involved in osteoclast biology [Poster presentation]. 43rd Annual European Calcified Tissue Society Congress, Rome, Italy.

Heusschen, R., Muller, J., BEGUIN, Y., Poirier, F., Cohen-Solal, M., Thijssen, V., & CAERS, J. (2016). Galectin-1 attenuates bone resorption by osteoclasts [Poster presentation]. EMBO Workshop: Transducing glycan information into function: Lessons from galectins.

Binsfeld, M., Muller, J., Lamour, V., De Veirman, K., De Raeve, H., Bellahcene, A., Van Valckenborgh, E., BARON, F., BEGUIN, Y., CAERS, J., & Heusschen, R. (2016). Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma. Oncotarget, 7, 37931-37943. doi:10.18632/oncotarget.9270
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC Kinase Inhibition with Saracatinib Limits the Development of Osteolytic Bone Disease in Multiple Myeloma [Poster presentation]. GIGA day 2016, Liège, Belgium.

Bolomsky, A., Heusschen, R., Schlangen, K., Schönfelder, K., Muller, J., Schreiner, W., Zojer, N., CAERS, J., & Ludwig, H. (2016). Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an attractive Novel Drug Target in Multiple Myeloma. Blood.
Peer Reviewed verified by ORBi

CAERS, J., de Larrea, C., Leleu, X., Heusschen, R., Zojer, N., Decaux, O., Kastritis, E., Minnema, M., Jurczyszyn, A., Beguin, Y., Wäsch, R., Palumbo, A., Dimopoulos, M., Mateos, M. V., Ludwig, H., & Engelhardt, M. (2016). The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. Oncologist, 21, 333-342. doi:10.1634/theoncologist.2015-0303
Peer Reviewed verified by ORBi

Heusschen, R.* , Muller, J.* , Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., BEGUIN, Y., Menu, E., Cohen-Solal, M., & CAERS, J. (2016). SRC Kinase Inhibition with Saracatinib Limits the Development of Osteolytic Bone Disease in Multiple Myeloma. Oncotarget, 7, 30712-30729. doi:10.18632/oncotarget.8750
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma [Paper presentation]. 31st General Annual Meeting of the Belgian Hematological Society, Brussels, Belgium.

Heusschen, R., Muller, J., Fillet, M., Vanderkerken, K., Thijssen, V., Cohen-Solal, M., BEGUIN, Y., & CAERS, J. (2016). Lectin-glycoprotein interactions in the diagnosis and biology of myeloma-related bone disease [Poster presentation]. 2nd Herbert Fleisch Workshop of the International Bone and Mineral Society, Brugge, Belgium.

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma. Blood.
Peer Reviewed verified by ORBi

Thijssen, V., Heusschen, R., CAERS, J., & Griffioen, A. (2015). Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochimica et Biophysica Acta - Reviews on Cancer, 1855 (2), 235-47. doi:10.1016/j.bbcan.2015.03.003
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma. Blood, 126 (23), 3018.
Peer Reviewed verified by ORBi

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., Beguin, Y., Heusschen, R., & CAERS, J. (2015). The anti-angiogenic peptide Anginex blocks osteoclastogenesis. Belgian Journal of Hematology, Abstracts book.
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma [Poster presentation]. 57th ASH Annual Meeting and Exposition, Orlando, United States - Florida.

Binsfeld, M., Fostier, K., Muller, J., Baron, F., Schots, R., Beguin, Y., Heusschen, R., & CAERS, J. (2014). Cellular immunotherapy in multiple myeloma : lessons from preclinical models. Biochimica et Biophysica Acta - Reviews on Cancer, 1846, 392-404. doi:10.1016/j.bbcan.2014.08.001
Peer Reviewed verified by ORBi

Binsfeld, M., Beguin, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Heusschen, R., Drion, P., Zilberberg, J., Bogen, B., Baron, F., & CAERS, J. (2014). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. PLoS ONE, 113764. doi:10.1371/journal.pone.0113764
Peer Reviewed verified by ORBi

Heusschen, R., Schulkens, I., Muller, J., Griffioen, A., BEGUIN, Y., Thijssen, V., & CAERS, J. (2014). Galectins in cancer: jacks of all trades [Paper presentation]. 19th World Congress on Advances in Oncology, Athens, Greece.

Heusschen, R.* , Schulkens, I.* , van Beijnum, J., Griffioen, A., & Thijssen, V. (2014). Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1842 (2), 284-92. doi:10.1016/j.bbadis.2013.12.003
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

CAERS, J., Binsfeld, M., Muller, J., Heusschen, R., & Beguin, Y. (2014). Gammapathie monoclonale de signification indéterminée : information destinée aux médecins référents. Revue Médicale de Liège, 69, 41-46.
Peer reviewed

Heusschen, R., Muller, J., Binsfeld, M., Thijssen, V., BEGUIN, Y., & CAERS, J. (2014). Galectin expression in the multiple myeloma microenvironment [Poster presentation]. GIGA day 2014, Liège, Belgium.

Heusschen, R., Schulkens, I., Muller, J., Griffoen, A., Beguin, Y., Thijssen, V., & CAERS, J. (2014). Galectins in cancer: jacks of all trades. International Journal of Molecular Medicine.
Peer Reviewed verified by ORBi

Schulkens, I.* , Heusschen, R.* , Van den boogaart, V., van Suylen, R.-J., Dingemans, A., Griffioen, A., & Thijssen, V. (2014). Galectin Expression Profiling Identifies Galectin-1 and Galectin-9Δ5 as Prognostic Factors in Stage I/II Non-Small Cell Lung Cancer. PLoS ONE, 9 (9), 107988. doi:10.1371/journal.pone.0107988
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Binsfeld, M., Heusschen, R., Lamour, V., Van Valckenborgh, E., Bellahcene, A., Baron, F., BEGUIN, Y., & CAERS, J. (2014). Multiple myeloma cells instruct myeloid-derived suppressor cells to release pro-angiogenic cytokines. Belgian Journal of Hematology.

Muller, J., CAERS, J., Binsfeld, M., Dubois, S., Carmeliet, G., BEGUIN, Y., & Heusschen, R. (2014). Galectin expression in the multiple myeloma microenvironment. Belgian Journal of Hematology.
Peer Reviewed verified by ORBi

Heusschen, R. (2013). The role of galectins in the vasculature [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/161190

Heusschen, R., Griffioen, A., & Thijssen, V. (2013). Galectin-9 in tumor biology: a jack of multiple trades. Biochimica et Biophysica Acta - Reviews on Cancer, 1836 (1), 177-85. doi:10.1016/j.bbcan.2013.04.006
Peer Reviewed verified by ORBi

Heusschen, R.* , Freitag, N.* , Tirado-Gonzalez, I., Barrientos, G., Moschansky, P., Munoz-Fernandez, R., Leno-Duran, E., Klapp, B., Thijssen, V., & Blois, S. (2013). Profiling lgals9 splice variant expression at the fetal-maternal interface: implications in normal and pathological pregnancy. Biology of Reproduction, 88 (1), 22. doi:10.1095/biolreprod.112.105460
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Heusschen, R., De Bree, M., Griffioen, A., & Thijssen, V. (2011). Identification and characterization of novel galectin-9 splice variants in endothelial cells. Cancer Research.
Peer Reviewed verified by ORBi

Heusschen, R., De Bree, M., Griffioen, A., & Thijssen, V. (2011). Identification and characterization of novel galectin-9 splice variants in endothelial cells [Poster presentation]. 102nd annual meeting of the American Association for Cancer Research, Orlando, United States - Florida.

Heusschen, R., Griffioen, A., & Thijssen, V. (2011). The role of galectin-9 splice variants in endothelial cells [Paper presentation]. Annual OOA Retreat, Texel, Netherlands.

Heusschen, R., De Bree, M., Griffioen, A., & Thijssen, V. (2011). Galectin-9 splice variants in endothelial cells: identification of novel variants and functional characterization. Angiogenesis.
Peer Reviewed verified by ORBi

Heusschen, R., De Bree, M., Griffioen, A., & Thijssen, V. (2011). Galectin-9 splice variants in endothelial cells: identification of novel variants and functional characterization [Paper presentation]. International Meeting on Angiogenesis, Amsterdam, Netherlands.

Heusschen, R., van Gink, M., Griffioen, A., & Thijssen, V. (2010). MicroRNAs in the tumor endothelium: novel controls on the angioregulatory switchboard. Biochimica et Biophysica Acta - Reviews on Cancer, 1805, 87-96. doi:10.1016/j.bbcan.2009.09.005
Peer Reviewed verified by ORBi

Contact ORBi